A Phase 1/2 interventional study of Epcoritamab (monotherapy) and Epcoritamab in Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma and Primary Mediastinal Large B Cell Lymphoma, sponsored by Genmab. Active, not recruiting at 15 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Genmab · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse — 16 open to participants now, 23 under way, 3 of them phase 3. epcoritamab · Lymphoma, Large B-Cell, Diffuse.
Among the 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse, this one is the 9th largest by enrollment, is one of 2 that started in 2020, is one of 3 in phase 1/2, reaches primary completion later than 5 of the 22 other live ones, and was the 1st registered.
1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →16 of the 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse are open now, in 5 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
University of Utah · Sites in United States
Ages 18+
Hospital Universitario Dr. Jose E. Gonzalez · Sites in Mexico
Ages 18–65
University of Miami · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 18+
By country, each count listing its studies:
epcoritamab: first FDA approval 2023 (EPKINLY), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 17 · Phase 3 3
First in 2020; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 78 is above the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 41 across the 24 interventional studies. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 24 have an industry lead sponsor. The 10 most frequent:
Genmab is the lead sponsor of 72 studies on the registry; 15 are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 13 (57%) have results posted.
13 studies in Lymphoma, Large B-Cell, Diffuse by Genmab: none open now, 9 under way, 4 of them phase 3. Of 3 finished, 2 (67%) have results posted.
Among the 13 studies in Lymphoma, Large B-Cell, Diffuse by Genmab, this one is the 9th largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2020, is one of 4 in phase 1/2, and was the 2nd registered.
Genmab’s Lymphoma, Large B-Cell, Diffuse studies by the year they started, since 2020.
8 of the studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06672705Timothy VoorheesEpcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders | 2026-12-31 |
| NCT05451810GenmabA Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma | 2027-03 |
| NCT06536049Yazeed SawalhaEpcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma | 2027-08-31 |
| NCT04542824GenmabTrial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) | 2027-09 |
| NCT07451652Hospital Universitario Dr. Jose E. GonzalezLow Dose Epcoritamab Plus GemOx in R/R DLBCL | 2027-09 |
Add all 8 to your calendar (.ics) → With an account.
Among the 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse, from their registry updates:
Among Genmab’s 13 in Lymphoma, Large B-Cell, Diffuse:
This tab as a report to print or save as PDF → With an account.
The trial is an open-label, multi-center safety and preliminary efficacy trial of epcoritamab (EPKINLY™) in Japanese participants with relapsed, progressive or refractory B-cell lymphomas and Japanese participants with B-cell lymphomas that have achieved partial response (PR) or complete response (CR) following prior standard of care (SOC). The trial consists of two parts: Part 1, dose escalation (phase 1), and Part 2, expansion (phase 2).
The purpose of the dose-escalation part of the trial is to determine the maximum tolerated dose (MTD) and the recommended Phase-2 dose (RP2D), as well as to establish the safety profile of epcoritamab in Japanese participants with relapsed, progressive or refractory B-cell lymphoma and Japanese participants with B-cell lymphomas that have achieved PR or CR.
In the expansion part, additional participants will be treated with epcoritamab, at the RP2D and the purpose is to further explore and determine the safety and efficacy of epcoritamab.
Part 2 of the trial will be initiated once the RP2D has been determined in Part 1. In Part 2, epcoritamab is investigated as a monotherapy and in combination with other SOC agents.
All participants in the trial will receive epcoritamab, as monotherapy or in combination with SOC. The following regimens will be investigated in Part 2:
Arm 1: epcoritamab monotherapy in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL)
Arm 2: epcoritamab + rituximab and lenalidomide (R2) in participants with R/R FL
Arm 3: epcoritamab + rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in participants with previously untreated DLBCL with high risk features
Arm 4: epcoritamab + gemcitabine and oxaliplatin (GemOx) in participants with R/R DLBCL who either failed prior autologous hematopoietic stem cell transplantation (ASCT), or are ineligible for autologous HSCT.
Arm 5: epcoritamab maintenance in participants with FL who achieve a CR or a PR following first line (1L)/second line (2L) SOC treatment
Main Inclusion Criteria:
Part 1:
Part 2 :
Arm 1:
Arm 2:
Arm 3:
One of following confirmed histologies (de novo or histologically transformed from FL or nodal marginal zone lymphoma) :
o DLBCL, not otherwise specified (NOS)
Arm 4:
One of following confirmed histologies (de novo or histologically transformed from FL or nodal marginal zone lymphoma) including:
o DLBCL, NOS.
o "Double-hit" or "triple-hit" DLBCL
Arm 5:
Main Exclusion Criteria:
Exclusion criteria for Part 2, Arms 2 through 5:
Arm 2:
Arm 3:
Arm 4:
Arm 5:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In participants with DLBCL/FL.
Biological: Epcoritamab (monotherapy)
In participants with R/R FL
Biological: Epcoritamab · Drug: Rituximab and lenalidomide
In participants with previously untreated DLBCL
Biological: Epcoritamab · Drug: Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
In participants with relapsed/refractory DLBCL
Biological: Epcoritamab · Drug: Gemcitabine and oxaliplatin
In participants with FL in CR or in PR following 1L or 2L SOC treatment
Biological: Epcoritamab (maintenance)
Epcoritamab will be administered subcutaneously in cycles of 4 weeks (i.e. 28 days)
Also known as: GEN3013, DuoBody®-CD3xCD20, EPKINLY™
Epcoritamab will be administered in combination with the respective SOC chemotherapy followed by epcoritamab monotherapy.
Also known as: GEN3013, DuoBody®-CD3xCD20, EPKINLY™
21-day cycles
Also known as: R-CHOP
Drug pages: Gemcitabine · Oxaliplatin
28-day cycles
Also known as: GemOx
28-day cycle for Cycle 1 and then 56-day cycle from Cycle 2 through 13
Also known as: GEN3013, DuoBody®-CD3xCD20, EPKINLY™
Drug pages: Rituximab · Lenalidomide
28-day cycles.
Also known as: R2
Part 1: Number of Participants with Treatment-emergent Adverse Events (TEAEs)
Time frame: From first dose until the end of the safety follow-up period (60 days after last dose), up to approximately 5 years
Part 1: Number of Participants with Dose Limiting Toxicities (DLTs)
Time frame: DLTs are assessed during the first cycle (28 days) in each cohort
Part 2, Arm 1: Objective Response Rate (ORR)
Time frame: Up to 1.5 years
Part 2, Arms 2-4: Number of Participants with DLTs
Time frame: DLTs are assessed during the first cycle (28 days) in arms 2-4
Part 2, Arms 2-5: Number of Participants with TEAEs
Time frame: From first dose until the end of the safety follow-up period (60 days after last dose), up to approximately 5 years
Both parts: Area-under-the-concentration-time curve from Time 0 to Time of last dose (AUClast)
Time frame: From first dose until treatment discontinuation, expected average of 1 year
Both parts: AUC from Time 0 to Infinity (AUCinf)
Time frame: From first dose until treatment discontinuation, expected average of 1 year
Both parts: Maximum (Peak) Plasma Concentration (Cmax)
Time frame: From first dose until treatment discontinuation, expected average of 1 year
Both parts: Time to Reach Cmax (Tmax)
Time frame: From first dose until treatment discontinuation, expected average of 1 year
Both parts: Pre-dose (Trough) Concentrations (Cthrough)
Time frame: From first dose until treatment discontinuation, expected average of 1 year
Both parts: Total Body Clearance of Drug from the Plasma (CL)
Time frame: From first dose until treatment discontinuation, expected average of 1 year
Both parts: Volume of Distribution (Vd)
Time frame: From first dose until treatment discontinuation, expected average of 1 year
Both parts: Elimination Half-life (t 1/2)
Time frame: From first dose until treatment discontinuation, expected average of 1 year
Both parts: Number of Participants with Anti-Drug-Antibodies (ADAs)
Time frame: From first dose until treatment discontinuation, expected average of 1 year
Part 2, Arm 1: Number of Participants with TEAEs
Time frame: From first dose until the end of the safety follow-up period (60 days after last dose), up to approximately 5 years
Part 1 and Part 2, Arms 2-5: ORR
Time frame: Up to 1.5 years
Both parts: CR Rate
Time frame: Up to 1.5 years
Both parts: Duration of Response (DOR)
Time frame: Up to 1.5 years
Both parts: Progression Free Survival (PFS)
Time frame: Up to 1.5 years
Part 2: Duration of CR (DoCR)
Time frame: Up to 1.5 years
Part 2: Time to Response (TTR)
Time frame: Up to 1.5 years
Part 1 and Part 2 arm 1: Time to Next Anti-lymphoma Therapy (TTNT)
Time frame: Up to 1.5 years
Both parts: Overall Survival (OS)
Time frame: Up to 1.5 years
Plan to share: No
Started Aug 2020 (actual). Primary completion is estimated for Sep 2027, 85 months after the start.
Of 51 industry-sponsored phase 1/2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 54 and three quarters within 99. This study's planned 85 months is above that.
Counting every sponsor, half of 108 studies reached it within 70 months; a quarter within 50 and three quarters within 98.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Epcoritamab
Lymphoma, Large B-Cell, Diffuse →